7 analysts have expressed a variety of opinions on Roivant Sciences ROIV over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 4 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $18.0, with a high estimate of $23.00 and a low estimate of $15.00. Marking an increase of 10.77%, the current average surpasses the previous average price target of $16.25.
Analyzing Analyst Ratings: A Detailed Breakdown
The analysis of recent analyst actions sheds light on the perception of Roivant Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $18.00 | - |
| Corinne Jenkins | Goldman Sachs | Raises | Buy | $18.00 | $16.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $18.00 | $17.00 |
| Neena Bitritto-Garg | Deutsche Bank | Raises | Buy | $15.00 | $14.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $23.00 | - |
| Andy Chen | Wolfe Research | Announces | Outperform | $17.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Lowers | Buy | $17.00 | $18.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Roivant Sciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Roivant Sciences compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Roivant Sciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Roivant Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Roivant Sciences analyst ratings.
About Roivant Sciences
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Financial Insights: Roivant Sciences
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Roivant Sciences's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 117.8%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13721.55%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Roivant Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 144.81% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Roivant Sciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 108.68% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Roivant Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
